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1. Introduction
Glaucoma treatments which partially destroyed the ciliary body started already in the
thirthies of the 20th century. Heat and cold were used for this purpose, delivered from
different devices such as hot needles, cryo applicators, ultrasound generators or radiation
devices. All these methods were successful in lowering introcular pressure, but many eyes
were lost and ended in a phthisis. The reasons of such disastrous outcomes is not fully
investigated in all details, but it is mostly assumed that the production of aqueous humor has
been reduced too much. In summary, the methods were called “cyclodestructive”, a wording
primarily related to the destruction of tissue in the ciliary body, but also making graphical the
high destructive potential to the eye.
With the invention of lasers, many CW-lasers were utilized for tissue coagulation of the ciliary
body, and the new word “cyclophotocoagulation” was created, also to distinguish photo- from
cryocoagulation (1–13).
For a long time, current opinion was to restrict cyclophotocoagulation to intractable cases
due to severe complications which had been observed by several authors (e.g. (14–21)).
Meanwhile, however, transscleral cyclophotocoagulation is proposed also as primary therapy
(22; 23).
An improvement of the coagulation was achieved by the introduction of contact methods (24),
however, efforts undertaken in the past to optimize therapy parameters (25–29) including
aspects of radiation transport (30; 31) could not solve the principal problem that the laser
burns cannot be observed directly.
Without information about coagulation success, dosage cannot be adjusted to the individual
situation which shows a strong inter- and intraindividual variation of optical properties of the
corresponding tissue (32). For the reasons mentioned, we had developed a real-time control
system (33; 34) to solve this problem.
2. Controlling device
During coagulation of the tissue, chemical and physical effects are induced which change the
optical properties, i.e. the transmission, absorption and reflection in this material (35). For the
ciliary body, this effect cannot be observed directly. However, the transmitted laser radiation
produces diffuse stray light which is partly reflected from the fundus and can be observed
from outside the eye by a sensor. The principle of the corresponding device is illustrated in
fig. 1. The light intensity monitored by the sensor during the laser exposure depends on many
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Fig. 1. Functional Diagram. The laser radiation passing through sclera and ciliary body is partly
reflected from the fundus and recorded by a detector D. The amplified electronical signal is digitized by
an A/D-converter, recorded by a computer and displayed on a screen in real time. The whole process is
initiated by pressing the foot-switch F, which starts the computer and closes one of the switches for
the laser device. The second one is closed by a semiconductor-relay R, which is controlled by the
computer. Exposure is stopped either if the operator (viewing the screen) releases his foot-switch F or if
the computer opens the relay R, when the recorded signal has fulfilled certain programmable criteria.
parameters such as fundus reflectivity, pupil width etc. and can therefore not be used directly
as an absolute measure of the coagulation stage of the tissue. However, the coagulation process
changes the light observed as function of time in any case. Therefore, this time dependence can
be used to monitor the progress of coagulation. The electronic signal has to be normalized to
its starting value, i.e., only relative values are used for further evaluation.
There are 2 ways the process can be controlled. First, the surgeon can interrupt the exposure
if the displayed curve of changing transmission has a certain shape. This is possible, but
difficult, because typical time scales are in the range of 0.1-0.5s, which is approximately
the surgeon’s own reaction time. As a second “operator”, the computer can interrupt the
exposure.
3. Physical parameters
3.1 Laser power
Laser power has to be adjusted in such a way that the target tissue is coagulated as selectively
as possible, thereby saving all surrounding tissues. The physical parameters describing this
470 Glaucoma - Basic and Clinical Concepts
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Fig. 2. Application to a Patient’s Eye
in context are the temperature gradient and the heat conduction, which determine the thermal
relaxation time. If laser power is too low, a long time is needed until coagulation starts. During
this time, a high portion of heat is already dissipated into the surrounding tissue. This results
in an unwanted large area of coagulated tissue, which can also be observed from the high
value of the total energy, the product of power and time. A very high laser power, on the
other hand, induces a steep temperature gradient with a higher risk of overheating parts of
the target tissue before the rest is sufficiently coagulated. Such overheated tissue has a high
probability of so-called “pop spots”. A pop spot is a local overheating of the tissue in which
the tissue membranes are disrupted by the steam pressure with an audible “pop” as in a pop
corn.
As a compromise, we preferably use a laser power of 5W for the 810nm diode laser in
Caucasian eyes and found the same value suitable for the 940nm laser in African eyes. Only
in very rare cases of buphthalmos with very thin sclera this value has to be reduced to 3W.
471ontrolled Cyclophotocoagulation
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3.2 Laser wavelength
The laser wavelength for transscleral cyclophotocoagulation must be selected in such a way
that the laser light is transmitted through the conjunctiva, the sclera and the ciliary muscle, and
that it is absorbed by the pigment epithelium of the ciliary body. These requirements, however,
can only be fulfilled approximatively, depending on the spectral characteristics of the eye.
Caucasian and African eyes strongly differ in the absorption and transmission of visible and
infrared radiation. If the absorption is too high, the fraction of energy already absorbed
in conjunctiva, sclera or ciliary muscle causes an unwanted overheating of these tissues.
Absorption and transmission of ocular tissues show a strong wavelength dependence (36).
The spectra shown is this paper are consistent with the fact that the flux density needed for
the 1064nm Nd:YAG laser is approximately 2-fold higher than with the 810nm diode laser.
They also show that the same behavior as with the 810nm laser in Caucasian eyes could be
expected with a 940nm laser in African eyes. In a few African eyes treated with the 810nm
laser in Mainz University Eye Hospital, the abovementioned real-time control did not work,
i.e. many pop spots occured. Therefore, after tests with African cadaver eyes in Ghana (43),
the 940nm laser was clinically established in Cameroun.
Applications of shorter wavelengths for transscleral cyclophotocoagulation in the visible red
range have been reported only by Scandinavian authors for a population with very lightly
pigmented eyes (8; 37; 38), again consistent with the spectra in (36).
3.3 Location
As location, we chose the transition region between pars plicata and pars plana of the ciliary
body, i.e., 3-3.5mm posterior to the limbus. We intend to coagulate at least a part of the
secreting tissue, but care should be taken of the ciliary muscle including fixation of zonula
fibers (which could be disintegrated), because the procedure should also be applicable to
phakic, accommodating eyes. The effectiveness of even higher limbus distances has been
proven by other authors (39). Fortunately, our real-time control shows optimal performance
just in the chosen limbus distance.
Normally, 360◦ are treated. The only exceptions are scleral lesions / thinned sclera,
particularly the areas of previous trabeculectomies.
3.4 Optic of the laser applicator
The laser applicator (the tip directly pressed on the eye) should be designed in such a way that
the optical power density at the conjunctiva is minimal and the power density in the target
tissue (ciliary body) is maximal. Focussing therefore seems to be a reasonable procedure.
Unfortunately, the outcome of focussing is rather poor. If a (spherical) lens is used, even
for a material with a high refractive index a relatively long focal width results, because the
refractive index of the sclera is similar to that of water, i.e., much larger than one. This
problem could be solved in principle by a so-called “gradient index lens” (40), for which
the focal width can be set to any position. But, our own measurements and calculations (31)
also with such optical devices have shown that diffuse multiple scattering in scleral tissue
largely neutralises the focussing effect. Fortunately, radiation transport can be optimised by
an appropriate choice of the diameter of the optical tip. As shown in (31), this diameter should
be larger than or at least equal to the thickness of the sclera. On the other hand, a smaller tip
diameter theoretically causes a higher pressure on the sclera leading to an improved optical
transmission (41; 42). Thus, both effects have to be balanced against each other by an optimal
72 Glaucoma - Basic and Clinical Concepts
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tip diameter. Tests in Caucasian and African cadaver eyes showed that a tip diameter of
1.5mm was optimal for Caucasian and of 1.95mm for African eyes.
3.5 Shape of transmission curves
Typical curves resulting from coagulation in porcine eyes, Caucasian cadaver eyes and in the
eyes of Caucasian patients are in detail reported in (33), see fig.3 for an example. The curves
of African eyes principally show the same shape, but with slightly different amplitudes from
minimum to maximum which therefore needed different software settings.
The shape of these curves (see fig.3) corresponds to the temperature change in the target tissue:
In the first, horizontal part (1), no irreversible chemical or physical effects occur, therefore the
transmission in the tissue remains constant. The temperature may increase to about 45-50◦C.
In the second, decreasing part (2), the transmission is reduced mainly by shrinkage of the
tissue. The temperature further increases to about 60-70◦C. After that, only minor changes
in the transmission occur (3), but the temperature increases to a value above 100◦C. Trapped,
overheated steam then disrupts tissue membranes in the “pop spot”. Since for the “wanted”
effect of irreversible coagulation, a temperature of about 55-60◦C is sufficient, the process
should be interrupted at the end of phase two. This is normally less than 1/3 of the time to
pop spot, because at the beginning of the coagulation, the temperature raise is steeper than
at the end due to heat dissipation to the neighbourhood. Fortunately, further heating above
60◦C but well below 100◦C is not critical, thus giving a relative safe “therapeutic window”
before a pop spot occurs.
4. Clinical applications
4.1 Indication
Controlled cyclophotocoagulation is indicated in all open angle glaucomas in which eye
drops do not effectively reduce the intraocular pressure. This includes cases of insufficient
compliance in industrial countries as well as developing countries in which eye drops are not
available or not effordable. In severe cases of hemorrhagical secondary glaucoma in blind eyes
even repeated controlled cyclophotocoagulation may be insufficient and should be replaced
by cryocoagulation.
4.2 Preoperative preparation and anesthesia
It is recommended to dilate the pupil preoperatively because it increases the
signal-to-noise-ratio of the detector of the real time control, but when the pupil cannot
be dilated, the procedure can be applied anyway.
Anesthesia can be a para- or retrobulbar injection, or a general anesthesia, or a combination
of topical anesthesia by eye drops and general analgesia (e.g. Propofol combined with a short
acting opioid). Topical anesthesia alone with eye drops is insufficient. In case of para- or
retrobulbary injections, it should be kept in mind that the risk of these injections is higher than
that of the controlled cyclophotocoagulation. Analgesia alone needs very high drug doses
when the simulataneous topical anesthesia is omitted.
4.3 Treatment
Generally, 16 spots are applied over 360◦. A larger number (24 spots) did not result
in a significantly higher IOP reduction, but in a significantly higher and longer lasting
473ontrolled Cyclophotocoagulation
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Fig. 3. Typical Transmission Curves. The recordings are from porcine eyes. The numbers (1,2,3)
and their meaning are explained in the text.
inflammation reaction (cells). An integrated instrument comprising laser source and
computer and its application in Cameroun is shown in fig.4.
4.4 Postoperative medication
After surgery, local antibiotics are applied once in order to prevent infections based on minor
(and prehaps overlooked) corneal or conjinctival lesions. Local steroids and Scopolamin or
Homatropine are applied until there are no more signs of inflammation (cells) visible at the
slitlamp.
4.5 Complications
Major complications such as intraocular bleedings, shallow anterior chamber, chorioideal
detachment, ocular hypotension <7mmHg or phthisis have not been observed during more
than 2000 treatments of Caucasian patients with the 810nm laser in the university eye hospital
of Mainz, Germany, nor in more than 1000 treatments of African patients with the 940nm laser
in the eye clinic at Acha Bafoussam, Cameroun. Such complications also did not come to our
knowledge from other hospitals using this method.
Some minor complications can happen from time to time:
Conjunctival hemorrhages can occur at the locations where the tip is placed on the
conjunctiva, particularly in patients with systemic anticoagulation. Depending on the
surgeons’ experience and care also corneal erosions can be produced. Intraocular iritis (cells)
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Fig. 4. Application in Camerounian Patients
mostly disappear after one or two days, and higher degrees of inflammation (fibrin exudation)
is extremely rare (<1% of the treatments).
In our opinion, also pop spots should be looked at as complications. Even if the probability of
pop spots is highly reduced by the real-time control of the coagulation, this probability is not
zero. In Caucasian eyes one or more pop spots occur in ≈20% of the eyes, in African eyes in
≈30%.
Even if visual acuity as a measure of unwanted side effects has been recorded pre- and
postoperatively, the data have not been evaluated systematically. They are often incomplete
and biased by the often unknown refraction and by additional reasons (e.g. cataract) that
worsens visual acuity. Nevertheless, a significant decrease following the treatment did not
occur. It did, however, in Mainz University eye hospital in one case that was treated with 24
spots in the starting phase. The reason was a macula edema. With the generally recommended
protocol of 16 spots no further macula edema was observed.
4.6 Influence on Intraocular Pressure (IOP)
4.6.1 Caucasian eyes
Despite the high treatment numbers in the University Eye Hospital Mainz, these patients
could not be followed up systematically because of the deduction rules of the health insurance.
Patients are referred from other doctors to the University Hospital, but seen again only in case
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of complications or isufficient treatment. Fig.5 shows the IOP of another German hospital
which could do a systematic follow-up without selection bias.
Fig. 5. Intraocular Pressure in European Eyes. The IOP of 40 eyes in which controlled
cyclophotocoagulation was the 1st and only glaucoma surgery is shown as function of the follow-up
time of 4 years. The numbers on the bottom of each column show the averages. (Picture by courtesy of
Dr. Gerl, Dr. Schmickler, Augenklinik Ahaus, Germany)
4.6.2 African eyes
272 eyes of 188 patients with primary open angle glaucoma were treated in the eye hospital
of Bafoussam, Cameroun. Follow-ups were scheduled for 1 day, 1 week, 1 month, 3 months,
6 months and 1 year after surgery. But mostly, patients were unable to meet such fixed dates.
Instead, if at all, they appeared more or less at random times after surgery. All individual IOP
changes at all recording times are shown in figs. 6 and 7.
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Fig. 6. Absolute Change in IOP The average of the starting IOP was 28.5mmHg.
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Fig. 7. Relative Change in IOP
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5. Discussion
Controlled cyclophotocoagulation with the 810nm laser for Caucasian and with the 940nm
laser for African glaucoma eyes is a method with nearly negligible complications. However,
the individual IOP reduction is not predictable.
Re-treatments are possible, but an interval of at least 4 weeks is recommended, because a
significant prostaglandine release for at least 2 weeks is an unavoidable concomittant of the
coagulation (45). The maximum number of re-treatments performed so far was 13 in an eye in
which no other glaucoma surgery was possible (only functioning eye of this patient, and this
eye had already multiple surgeries). The function of the eye could be preserved at an IOP that
finally reached 8mmHg. Even if not explicitely shown for humans, at least a partial recovery
must be assumed for the coagulated tissue.
The low complication risk can be understood as a result of the low energy load compared with
the uncontrolled coagulation. In Caucasian eyes, the energy per spot is ≈1.5J and in Africans
≈1.0J, which is to be compared with the much higher values reported from other authors: 3.6J
(13) or 2.2J to 3.3J (30) in Caucasians and 2.25 to 3.125J in Africans (22). Nd:YAG-laser values
are even higher (44).
In Africans, IOP reduction is obviously higher and complication rate lower compared to the
uncontrolled coagulation with the 810nm laser (22).
As a consequence of the high power (5W) and low exposure time (≈0.2s in Africans and≈0.3s
in Caucasians), the major fraction of energy is thermalized in the highest absorbing tissue, i.e.
in the (black) pigmented ciliary epithelium, thus causing a selective coagulation of this target
tissue.
As a major drawback, cyclophotocoagulation in general may result in conjunctival scarring
which interferes with other procedures such as trabelectomy or shunt tube placement.
However, the probability of such conjunctival scarring is reduced by a more selective
approach.
To apply such a high power without the risk of very many pop spots, the real time control is
an indispensable necessity of the device.
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